<DOC>
	<DOCNO>NCT01766388</DOCNO>
	<brief_summary>The primary goal study examine efficacy feasibility mifepristone combine misoprostol medical abortion regimen terminate pregnancy 13-22 week Armenia .</brief_summary>
	<brief_title>Mifepristone Misoprostol Mid-trimester Termination Pregnancy Armenia</brief_title>
	<detailed_description>Women deem eligible study provider give inform consent . They take 200 mg mifepristone orally study clinic . In 24-44 hour , return clinic induction misoprostol . They admit inpatient clinic take 400 mcg buccal misoprostol every 3 hour fetus placenta expel . If full expulsion 10 dos misoprostol , provider use discretion determine appropriate clinical course action . After respond question experience procedure , woman discharge study .</detailed_description>
	<mesh_term>Mifepristone</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>Pregnancy 1322 week ' gestation Good general health Meeting legal criterion obtain abortion Presenting close cervical os vaginal bleeding Live fetus time presentation service Willingness undergo surgical completion necessary No contraindication study procedure , accord provider Woman willing able consent procedure , either read consent document consent document read Willingness follow study procedure Known previous transmural uterine incision Known allergy mifepristone misoprostol/prostaglandin contraindication use mifepristone misoprostol Parity great 5 Any contraindication vaginal delivery , include placenta previa Presentation active labor ( defined moderate severe contraction every 10 minute less )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>